Top News

Vertex Receives European Approval for KALYDECO? (ivacaftor) in Eight Non-G551D Gating Mutations

Business Wire, 31.07.2014

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has approved KALYDECO? (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Today's approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2014. KALYDECO was first approved in Europe in July 2012 for people with CF ages 6 and older who have the G551D mutation, which is the most common gating mutation. The eight additional gating mutations included in today's approval are: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D. In Europe, approximately 250 people ages 6 and older have one of these non-G551D gating mutations.

more

Next Event

 

Community Login







Harlan Laboratories Ltd.

Bachem Holding AG

loroch.ch

 Wissenschaft im Gespraech | Den Naturwissenschaften fehlt der Nachwuchs | Schweizer Radio DRS

The potential in the land

LRC TriCEPS™ technology

BBC - End of Drug Discovery